Proteomics

Dataset Information

0

Quantitative proteomics analysis revealed C1GALT1 depletion in ECC-1 cells mimics an aggressive endometrial cancer phenotype observed in cancer patients with low C1GALT1 expression.


ABSTRACT: Endometrial cancer (EC) is the most common cancer of female reproductive organs. Because some low-grade ECs might also experience tumor recurrence after surgery and a worse prognosis, the study of alterations related to EC pathogenesis of the disease might help to get insights into underlying mechanisms involved in EC development and metastasis and identify novel markers associated to the disease. Here, low C1GALT1 protein expression levels were associated to a more aggressive phenotype of EC. Then, we aimed at investigating the role of C1GALT1 in EC progression by quantitative proteomics. ECC-1 cells were used as endometrioid EC model, and the effect of C1GALT1 depletion was analyzed using C1GALT1 specific short hairpin RNAs (shRNA) in comparison to SCRAMBLE shRNA. SILAC and mass spectrometry analysis were performed to identify and quantify dysregulated proteins associated with C1GALT1 depletion in the cell extract and secretome proteome of shC1GALT1 and SCRAMBLE ECC-1 cells. Out of 5208 proteins identified and quantified by LC-MS/MS, 76 and 143 proteins showed dysregulation (fold-change ≥1.5 or ≤0.67) in shC1GALT1 ECC-1 cells’ extracts and secretome, respectively. Nine dysregulated proteins were selected for validation by orthogonal techniques, confirming their dysregulation upon C1GALT1 depletion. Bioinformatics analyses pointed out to an increase in pathways and dysregulated proteins that associated with more aggressive phenotype. This finding was corroborated by loss-of-function cell-based assays. A higher proliferation, invasion, migration, colony formation and angiogenesis capacity of C1GALT1 depleted cells was observed. Finally, the negative protein expression correlation found by proteomics between C1GALT1 and LGALS3 was confirmed by IHC in actual EC samples, suggesting C1GALT1 stably depleted ECC-1 cells mimic the aggressive phenotype of EC cells and might be useful for the identification and validation of potential markers in aggressive ECs.

INSTRUMENT(S): Q Exactive HF

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Epithelial Cell

DISEASE(S): Endometrial Cancer

SUBMITTER: Ana Montero Calle  

LAB HEAD: Rodrigo Barderas

PROVIDER: PXD032271 | Pride | 2023-07-20

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
SEARCH_Cellular_extract.zip Other
SEARCH_Secretome.zip Other
SILAC_Cellular_extract_Forward_F1.raw Raw
SILAC_Cellular_extract_Forward_F2.raw Raw
SILAC_Cellular_extract_Forward_F3.raw Raw
Items per page:
1 - 5 of 26
altmetric image

Publications

In-depth quantitative proteomics analysis revealed C1GALT1 depletion in ECC-1 cells mimics an aggressive endometrial cancer phenotype observed in cancer patients with low C1GALT1 expression.

Montero-Calle Ana A   López-Janeiro Álvaro Á   Mendes Marta L ML   Perez-Hernandez Daniel D   Echevarría Irene I   Ruz-Caracuel Ignacio I   Heredia-Soto Victoria V   Mendiola Marta M   Hardisson David D   Argüeso Pablo P   Peláez-García Alberto A   Guzman-Aranguez Ana A   Barderas Rodrigo R  

Cellular oncology (Dordrecht, Netherlands) 20230206 3


<h4>Background</h4>Endometrial cancer (EC) is the most common cancer of the female reproductive organs. Despite the good overall prognosis of most low-grade ECs, FIGO I and FIGO II patients might experience tumor recurrence and worse prognosis. The study of alterations related to EC pathogenesis might help to get insights into underlying mechanisms involved in EC development and progression.<h4>Methods</h4>Core tumoral samples were used to investigate the role of C1GALT1 in EC by immunohistochem  ...[more]

Similar Datasets

2015-11-25 | PXD002848 | Pride
2022-02-28 | PXD005658 | Pride
2023-10-24 | PXD042208 | Pride
2024-03-25 | PXD049328 | Pride
2020-04-30 | PXD014215 | Pride
2018-10-16 | PXD010632 | Pride
2018-11-21 | E-MTAB-6235 | biostudies-arrayexpress
2022-11-05 | PXD033120 | Pride
2020-12-11 | PXD016816 | Pride
2021-07-02 | PXD025169 | Pride